首页> 美国卫生研究院文献>CPT: Pharmacometrics Systems Pharmacology >Mining the Synergistic Core Allosteric Modules Variation and Sequencing Pharmacological Module Drivers in a Preclinical Model of Ischemia
【2h】

Mining the Synergistic Core Allosteric Modules Variation and Sequencing Pharmacological Module Drivers in a Preclinical Model of Ischemia

机译:缺血前临床模型中协同核心变构模块变异的挖掘和药理模块驱动程序的排序

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Identifying the variation of core modules and hubs seems to be critical for characterizing variable pharmacological mechanisms based on topological alteration of disease networks. We first identified a total of eight core modules by using an approach of multiple modular characteristic fusing (MMCF) from different targeted networks in ischemic mice. Interestingly, the value of module disturbance intensity (MDI) increased in drug combination group. Second, we redefined a weak allosteric module and a strong allosteric module. Then, we identified 15 pharmacological module drivers (PMDs) by leave‐one‐out screening with a cutoff of two folds, which were at least, in part, validated by expression and variation of topological contribution. Finally, we revealed the fusional and emergent variation of PMD in core modules contributing to multidimensional synergistic mechanism in ischemic mice and rats. Our findings provide a new set of drivers that might promote the pharmacological modular flexibility and offer a potential avenue for disease treatment.
机译:识别核心模块和集线器的变异对于表征基于疾病网络拓扑变化的可变药理机制似乎至关重要。我们首先通过使用来自缺血小鼠不同目标网络的多重模块特征融合(MMCF)方法,确定了总共八个核心模块。有趣的是,药物组合组的模块干扰强度(MDI)值增加。其次,我们重新定义了弱变构模块和强变构模块。然后,我们通过留一法筛选筛选出了15种药理学模块驱动剂(PMD),其截留倍数为2倍,这至少部分通过拓扑贡献的表达和变化进行了验证。最后,我们揭示了PMD在核心模块中的融合和突现变化,有助于缺血小鼠和大鼠的多维协同机制。我们的发现提供了一组新的驱动因素,可能会促进药理学模块的灵活性,并为疾病治疗提供潜在途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号